Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York. Show more

345 Park Avenue South, New York, NY, 10010, United States

Biotechnology

Healthcare

Market Cap

272.6M

52 Wk Range

$2.77 - $7.82

Previous Close

$5.04

Open

$4.90

Volume

511,530

Day Range

$4.86 - $5.13

Enterprise Value

120.1M

Cash

155.6M

Avg Qtr Burn

-16.95M

Insider Ownership

2.14%

Institutional Own.

78.58%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
IV Choline chloride Details Intestinal failure associated liver disease, Long-term parenteral support	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TARA-002 Details Non-muscle invasive bladder cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TARA-002 Details Lymphatic malformations (LMs)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.